FOR IMMEDIATE RELEASE

Contact: Christine Crooks, Director of Marketing
Carmel Pharma, Inc. 1-866-487-9250 ext 202

CARMEL PHARMA, INC. SECURES THEIR GOLD STANDARD STATUS IN SAFE HANDLING, WITH THE LAUNCH OF THE Y-SITE CONNECTOR, THE LATEST PHASEAL SYSTEM COMPONENT

Columbus, Ohio, July 18, 2006–Carmel Pharma, Inc., has introduced a new safety component with their PhaSeal System. The Y-Site Connector component provides a designated dry connection port for an IV push when administering hazardous drugs. It affords accessibility to the IV line without interfering with other ports that are in use. As with the other components that make up The PhaSeal System, this new feature is equipped with a purposed safety design. Its unique extension tubing has a permanently affixed luer-lock connector with a double membrane designed to prevent any occurrence of accidental leaks or disconnections.

The PhaSeal System remains the gold standard for the safe handling of hazardous drugs. With over 9 peer-reviewed clinical studies currently available, PhaSeal has ample documentation to support their claim that it is the only available Closed-System Drug Transfer Device on the market today. PhaSeal eliminates hazardous drug interaction with the environment from preparation through administration to waste disposal.

The PhaSeal System is manufactured in Gothenburg, Sweden and is distributed from its U.S. affiliate office in Columbus, OH. PhaSeal has been in use in the U.S. since 2000 and has been implemented in over 400 cancer facilities in the United States, including M.D. Anderson in Houston, TX, Texas Children’s and UCSF. If you have questions regarding the PhaSeal System or Carmel Pharma, Inc., please contact Christine Crooks, Director of Marketing at 1-866-487-9250 ext.202.